Items Tagged ‘mantle cell lymphoma’

November 6th, 2017

FDA approves Calquence Treatment for Treatment of Mantle Cell Lymphoma

By

The U.S. Food and Drug Administration has granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy.  Mantle cell lymphoma is a particularly aggressive cancer and new treatments are needed for patients who have not responded to treatment or have relapsed, Mantle […]

View full entry

Tags: Calquence acalabrutinib, Lymphoma, mantle cell lymphoma, Mantle Cell Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma


August 9th, 2017

Acalabrutinib granted Breakthrough Therapy Designation for the Treatment of Mantle Cell Lymphoma

By

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for acalabrutinib for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Acalabrutinib is a highly-selective, potent Bruton tyrosine kinase (BTK) inhibitor being evaluated for the treatment of multiple B-cell cancers. The Breakthrough Therapy Designation […]

View full entry

Tags: Acalabrutinib, Bruton tyrosine kinase, mantle cell lymphoma, Mantle Cell Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma